Schizophrenia Outpatient Health Outcomes study: twelve-month findings

References

• American Psychiatric AssociationPractice guidelines for the treatment of patients with schizophreniaAm J Psychiatry2001154163
   Google Scholar
• Expert Consensus PanelsThe Expert Consensus Guideline Series: treatment of schizophrenia 1999J Clin Psychiatry199960Suppl 11182
   Google Scholar
• LehmanAFSteinwachsDMTranslating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendationsSchizophr Bull1998241109502542
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceTechnology appraisal. Guidance No. 43. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophreniaLondonNICE2002 Available from: http://www.nice.org.uk/nicemedia/live/11786/43628/43628.pdfAccessed July 7, 2011
   Google Scholar
• ThornlyBAdamsCContent and quality of 2000 controlled trials in schizophrenia over 50 yearsBMJ1998317118111849794850
   PubMed Web of Science ®Google Scholar
• HoferAHummerMHuberRKurzMWalchTFleischhackerWWSelection bias in clinical trials with antipsychoticsJ Clin Psychopharmacol20002069970211106145
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGPollackSLernersGSubject selection biases in clinical trials: data from a multicenter schizophrenia treatment studyJ Clin Psychopharmacol1996161701768690832
   PubMed Web of Science ®Google Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ20003211371137611099280
   PubMed Web of Science ®Google Scholar
• SchoolerNRTollefsonGDTranPVGheuensJGrebbJAComments on article by Tran and colleagues, ‘Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders’J Clin Psychopharmacol1998181741799555605
   PubMed Web of Science ®Google Scholar
• KasperSKufferleBComments on ‘Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders’ by Trans and AssociatesJ Clin Psychopharmacol1998183533569690709
   PubMed Web of Science ®Google Scholar
• KapurSRemingtonGAtypical antipsychotics: new directions and new challenges in the treatment of schizophreniaAnn Rev Med20015250351711160792
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry200916615216319015230
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETJonesPBfor SOHO Study Group. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitmentActa Psychiatr Scand200310722223212580830
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETFrewerPfor SOHO Study GroupThe European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatmentActa Psychiatr Scand2003107Suppl 41619
   Google Scholar
• HaroJMEdgellENovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-months results of the pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand200511122023115701107
   PubMed Web of Science ®Google Scholar
• LambertMHaroJMNovickDOlanzapine versus other antipsychotics in actual outpatient settings: six months tolerability results from the European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand200511123224315701108
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology: Revised EditionWashington, DCUS Department of Health, Education, and Welfare1976
   Google Scholar
• HaroJMKamathSAOchoaSfor the SOHO Study GroupThe Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand2003107Suppl 4161623
   Web of Science ®Google Scholar
• WilliamsAEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• HaroJMAssessment of remission in schizophrenia with the CGI and CGI-SCH scalesActa Psychiatr Scand200811715617970843
   PubMed Web of Science ®Google Scholar
• GardnerDMMurphyALO’DonnellHCentorrinoFBaldessariniRJInternational consensus study of antipsychotic dosingAm J Psychiatry201016768669320360319
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPfor the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKLönnqvistJEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ200633322416825203
   PubMed Web of Science ®Google Scholar
• PrietoLNovickDSacristanJAfor the SOHO Study GroupA Rasch model analysis to test the cross-cultural validity of the Euro-Qol-5D (EQ-5D) in the Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2003107Suppl 4162429
   Web of Science ®Google Scholar
• PrietoLSacristanJAHormaecheaJAGomezJCEuro-Qol-5D (a generic health-related quality of life measure); psychometric validation in a sample of schizophrenic patientsEur Neuropsychopharmacol200212Suppl 3300
   Google Scholar
• RevickiDAGendusoLAHamiltonSHGanoczyDBeasleyCMOlanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trialQual Life Res1999841742610474283
   PubMed Web of Science ®Google Scholar
• RosenheckRCramerJXuWA comparison of clozapine and haloperidol in hospitalised patients with refractory schizophreniaN Engl J Med19973378098159295240
   PubMed Web of Science ®Google Scholar
• HamiltonSHEdgellETRevickiDABreierAFunctional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sampleInt Clin Psychopharmacol20001524525510993126
   PubMed Web of Science ®Google Scholar
• TollefsonGDBeasleyCMJrTranPVOlanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration studyAm J Psychiatry19971544574659090331
   PubMed Web of Science ®Google Scholar
• McGorryPDKillackeyELambertMElkinsKLambertTSummary Australian and New Zealand Clinical Practice Guidelines for the treatment of schizophreniaAustralas Psychiatry200311113
   Google Scholar
• ConleyRRMahmoudRA randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorderAm J Psychiatry200115876577411329400
   PubMed Web of Science ®Google Scholar
• CurranMPPerryCMSpotlight on amisulpride in schizophreniaCNS Drugs20021620721111888341
   PubMed Web of Science ®Google Scholar
• CutlerAJGoldsteinJMTumasJARelated dosing and switching strategies for quetiapine fumarateClin Ther20022420922211911552
   PubMed Web of Science ®Google Scholar
• SpinaEAvenosoAFacciolaGRelationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neurolepticsPsychopharmacology2000148838910663421
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGAbrahamDKisslingWEfficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophr Res19993551689988841
   PubMed Web of Science ®Google Scholar
• TarsyDBaldessariniRJTaraziFIEffects of newer antipsychotics on extrapyramidal functionCNS Drugs200216234511772117
   PubMed Web of Science ®Google Scholar
• TranPVHamiltonSHKuntzAJDouble-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disordersJ Clin Psychopharmacol1997174074189315992
   PubMed Web of Science ®Google Scholar
• BobesJGarc A-PortillaMPRejasJFrequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE studyJ Sex Marital Ther20032912514712623765
   PubMed Web of Science ®Google Scholar
• WiechAHaddadPMAntipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature reviewBr J Psychiatry200318219920412611781
   PubMed Web of Science ®Google Scholar
• DavidSRTaylorCCKinonBJBreierAThe effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaClin Ther2000221085109611048906
   PubMed Web of Science ®Google Scholar
• TurronePKapurSSeemanMVFlintAJElevation of prolactin levels by atypical antipsychoticsAm J Psychiatry200215913313511772702
   PubMed Web of Science ®Google Scholar
• AronneLJEpidemiology, morbidity, and treatment of overweight and obesityJ Clin Psychiatry200162Suppl 23132211603881
   PubMed Web of Science ®Google Scholar
• SussmanNThe implications of weight changes with antipsychotic treatmentJ Clin Psychopharmacol200323Suppl 1S21S2612832946
   PubMed Web of Science ®Google Scholar
• McIntyreRSManciniDABasileVSMechanisms of antipsychotic-induced weight gainJ Clin Psychiatry200162Suppl 23232911603882
   PubMed Web of Science ®Google Scholar
• AllisonDBMackellJAMcDonnellDDThe impact of weight gain on quality of life among persons with schizophreniaPsychiatr Serv20035456556712663847
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry19991561686169610553730
   PubMed Web of Science ®Google Scholar
• BasileVSMasellisMMcintyreRSMeltzerHYLiebermanJAKennedyJLGenetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzleJ Clin Psychiatry200162Suppl 23456611603885
   PubMed Web of Science ®Google Scholar
• LeffJSartoriusNJablenskyAKortenAErnbergGThe International Pilot Study of Schizophrenia: five-year follow-up findingsPsychol Med1992221311451574549
   PubMed Web of Science ®Google Scholar
• DossenbachMErolAel Mahfoud KessaciMfor the IC-SOHO Study GroupEffectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidolJ Clin Psychiatry20046531232115096069
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHYeWFlynnJFujikoshiSNakaharaNTakahashiMClinical and functional outcomes for patients with schizophrenia treated with olanzapine: One-year naturalistic outcomes for inpatients and outpatients in JapanClin Neuropsychopharmacol Ther201124555
   Google Scholar
• Ascher-SvanumHYeWFlynnJNakaharaNTakahashiMClinical and functional outcomes in the naturalistic treatment of inpatients and outpatients with schizophrenia in JapanPresented at the 164th Annual Meeting of the American Psychiatric AssociationMay 14–18, 2011Honolulu, HI
   Google Scholar
• ConcatoJShahNHorwitzRIRandomized, controlled trials, observational studies, and the hierarchy of research designsN Engl J Med20003421887189210861325
   PubMed Web of Science ®Google Scholar
• HaroJMKontodimasSNegrinMARatcliffeMSuarezDWindmeijerFMethodological aspects in the assessment of treatment effects in observational health outcomes studiesAppl Health Econ Health Policy20065112516774289
   PubMedGoogle Scholar
• SimpsonGMAngusJWSA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar